XBiotech Inc. Stock: price and insider trades · United States
1 insider bought €634k of shares over the last 90 days, the latest by SIMARD JOHN, filed 28 Oct 2026.
XBiotech Inc.: what insiders have been doing
Every trade that managers of XBiotech Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 28 October 2025 and 28 October 2026, 1 insider published 1 filing.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €634k, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive. Biggest ticket of the year: €634k, bought by Simard John and made public on 28 October 2026.
With 1 filing in twelve months, the company is quieter than the median of 24 filings across the 3,170 companies we follow on the same exchange. Looking back to 2015, when coverage begins, insiders filed 24 purchases and 64 sales.
The last insider purchase was made public on 28 October 2026, 11 days ago.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +89.6%Entry US$7.80 · Close at T+365 US$14.79
- +24.6%Entry US$9.54 · Close at T+365 US$11.89
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 368,524 shares@ US$1.93Common StockSEC:0001193125-26-435894:0Canonical exit: 24 Jan 2027 (T+90)
- 33,000 shares@ US$13.070.5% of flowCommon StockSEC:0001209191-22-009745:1
- 17,000 shares@ US$13.32189.6% of flowCommon StockSEC:0001209191-22-009745:0
- 213,493 shares@ US$11.712.2% of flowCommon StockSEC:0001209191-22-003158:1
- 250,000 shares@ US$10.00100.0% of flowCommon StockSEC:0001209191-22-003158:0
- 18,000 shares@ US$12.770.3% of flowCommon StockSEC:0001209191-21-060523:1
- 10,875 shares@ US$12.830.2% of flowCommon StockSEC:0001209191-21-060523:2
- 21,125 shares@ US$12.900.3% of flowCommon StockSEC:0001209191-21-060523:3
- 39,286 shares@ US$12.4520.9% of flowCommon StockSEC:0001209191-21-060523:0
- 14,218 shares@ US$12.660.2% of flowCommon StockSEC:0001209191-21-059849:1
- 10,714 shares@ US$12.530.2% of flowCommon StockSEC:0001209191-21-059849:2
- 23,681 shares@ US$13.084913.2% of flowCommon StockSEC:0001209191-21-059849:0
- 16,396 shares@ US$13.410.3% of flowCommon StockSEC:0001209191-21-058475:1
- 18,558 shares@ US$13.070.3% of flowCommon StockSEC:0001209191-21-058475:2
- 19,684 shares@ US$13.230.3% of flowCommon StockSEC:0001209191-21-058475:3
- 6,263 shares@ US$14.26853.8% of flowCommon StockSEC:0001209191-21-058475:0
- 11,418 shares@ US$14.490.2% of flowCommon StockSEC:0001209191-21-057877:1
- 29,890 shares@ US$14.810.6% of flowCommon StockSEC:0001209191-21-057877:2
- 9,892 shares@ US$14.68056.1% of flowCommon StockSEC:0001209191-21-057877:0
- 16,860 shares@ US$15.240.3% of flowCommon StockSEC:0001209191-21-057295:1
- 19,669 shares@ US$15.140.4% of flowCommon StockSEC:0001209191-21-057295:2
- 13,471 shares@ US$15.0638.5% of flowCommon StockSEC:0001209191-21-057295:0
- 50,000 shares@ US$18.14737.9% of flowCommon StockSEC:0001209191-21-047105:0
- 10,000 shares@ US$4.40100.0% of flowCommon SharesSEC:0001209191-21-046265:0
- 25,000 shares@ US$7.76100.0% of flowCommon SharesSEC:0001209191-21-046266:0
25 of 140 declarations
About XBiotech Inc.
XBiotech Inc. (NASDAQ: XBIT) is a U.S.-listed biotechnology company headquartered in Austin, Texas, United States. For French, Belgian and Swiss investors, it should be viewed as a clinical-stage biopharma company focused on the discovery, development and eventual commercialization of therapeutic antibodies derived from natural human immunity. The company describes itself as fully integrated, combining research, development and manufacturing capabilities on its Texas campus. XBiotech was incorporated in Canada on March 22, 2005, later building out its U.S. operating structure through XBiotech USA, Inc., incorporated in Delaware in 2007; its corporate headquarters are now in Austin, Texas. ([investors.xbiotech.com](https://investors.xbiotech.com/static-files/481a963d-2501-47fc-b160-054019e090bd))
Its investment case is centered on the True Human™ antibody platform. Rather than relying on traditional antibody engineering methods, XBiotech says it isolates antibodies directly from people with natural immunity to disease. That distinction is a core part of its scientific and commercial narrative, because the company believes this approach may support favorable tolerability and safety characteristics. XBiotech’s portfolio has historically spanned inflammation, immunology, oncology and infectious disease, with prior work in colorectal cancer, dermatology, staphylococcal infections and Ebola-related research. The company is still best understood as a pipeline-driven biotech rather than a product-rich commercial pharma business. ([xbiotech.com](https://www.xbiotech.com/?utm_source=openai))
Read moreShow less
Among the key assets, XBiotech highlights bermekimab, its anti-IL-1 alpha antibody, and Natrunix, another IL-1α-targeting program. Management has also emphasized that it retained rights to continue developing next-generation anti-IL-1α therapeutics after the 2019 acquisition of bermekimab by Janssen Biotech, which supports the strategic value of the platform and its intellectual property. In March 2026, the company announced that the U.S. Patent and Trademark Office granted three new patents covering True Human™ antibodies specific to interleukin-1 alpha, a meaningful reinforcement of its patent estate and a positive sign for long-term platform optionality. ([xbiotech.com](https://www.xbiotech.com/news/xbiotech-awarded-three-us-patents))
On the competitive front, XBiotech operates in a crowded field dominated by large pharmaceutical groups and numerous specialized biotech peers in immunology and oncology. As a smaller clinical-stage company, it must rely on scientific differentiation, robust clinical readouts, and strong IP protection to create value. One relative strength is its operational footprint: the company has a 48-acre campus in Austin with research, manufacturing and office infrastructure, and it announced plans in 2024 to construct an additional state-of-the-art R&D facility to support future development and possible commercialization efforts. That vertical integration can be advantageous if programs progress successfully. ([xbiotech.com](https://www.xbiotech.com/about-us))
Recent catalysts have focused on pipeline execution. In June 2024, XBiotech reported phase 1/2 data in advanced pancreatic cancer suggesting improved tolerability and encouraging efficacy trends for Natrunix combined with standard chemotherapy. Its investor materials also show that the company paused its rheumatology program in December 2024, indicating portfolio prioritization and capital discipline. For equity investors, XBiotech remains a high-risk/high-upside biotechnology story: the main value drivers are clinical data, patent expansion, and the ability to translate its True Human™ platform into partnering, licensing or eventual product revenues. ([investors.xbiotech.com](https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-results-randomized-double-blinded-phase-12-study/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
